BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 22615459)

  • 1. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
    Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
    Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ig gene analysis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjögren's syndrome patients.
    Hamza N; Hershberg U; Kallenberg CG; Vissink A; Spijkervet FK; Bootsma H; Kroese FG; Bos NA
    J Immunol; 2015 Jan; 194(2):514-21. PubMed ID: 25488989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minor salivary gland immunohistology in the diagnosis of primary Sjögren's syndrome.
    Salomonsson S; Rozell BL; Heimburger M; Wahren-Herlenius M
    J Oral Pathol Med; 2009 Mar; 38(3):282-8. PubMed ID: 18793250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
    Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S
    Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of N-Glycosylation Sites in Immunoglobulin Heavy Chain Genes During Local Expansion in Parotid Salivary Glands of Primary Sjögren Patients.
    Visser A; Doorenspleet ME; de Vries N; Spijkervet FKL; Vissink A; Bende RJ; Bootsma H; Kroese FGM; Bos NA
    Front Immunol; 2018; 9():491. PubMed ID: 29662487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
    Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
    Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
    Haacke EA; van der Vegt B; Meiners PM; Vissink A; Spijkervet FK; Bootsma H; Kroese FG
    Clin Exp Rheumatol; 2017; 35(2):317-320. PubMed ID: 27908305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
    Abdulahad WH; Kroese FG; Vissink A; Bootsma H
    J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FcRL4
    Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
    J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of CD4+ CD25+ regulatory T cells in peripheral blood and salivary gland of patients with primary Sjögren's syndrome].
    Li XM; Li XP; Qian L; Wang GS; Zhang H; Zhei ZM; Li Q; Chen K; Wang XQ; Wang YP
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1034-6. PubMed ID: 17672966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A
    Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of parotid gland biopsy in early detection of lymphoma in primary Sjogren's syndrome].
    Vasil'iev VI; Logvinenko OA; Probatova NA; Kokosadze NV; Gorodetskiĭ VR; Kovrigina AM; Kondrat'eva TT; Mitrikov BV; Gaĭduk IV; Safonova TN; Simonova MV; Radenska-Lopovok SG; Varlamova EIu
    Ter Arkh; 2009; 81(6):20-7. PubMed ID: 19663187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome.
    Gellrich S; Rutz S; Borkowski A; Golembowski S; Gromnica-Ihle E; Sterry W; Jahn S
    Arthritis Rheum; 1999 Feb; 42(2):240-7. PubMed ID: 10025917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
    Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G
    Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab in primary Sjögren's syndrome: a ten-year journey.
    Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
    Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
    Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
    J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 antibody in primary Sjögren's syndrome management.
    Chen S; Liu Y; Shi G
    Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.